Argomento: Biomarkers and treatment response or prognosis. Working towards personalized MS treatment, the epidemiology of MS: environmental factors, genetics, and their impact on disease risk and progression, Innate immunity and the pathogenesis of MS. - Ente organizzatore: Merck S.p.A.
Periodo di svolgimento dell’iniziativa:
(maggio 21, 2021 - )